NCT03226418 2026-03-10
Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
University of Nebraska
Phase 2 Completed
Clinical Trials
10 trialsNCT02038777 2025-02-26
A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies
Pfizer
Phase 1 Completed
NCT00953758 2024-04-25
A Study Of PF-04449913 In Select Hematologic Malignancies
Pfizer
Phase 1 Completed
NCT01286467 2024-03-06
A Study Of PF-04449913 Administered Alone In Select Solid Tumors
Pfizer
Phase 1 Completed
NCT04842604 2023-12-18
Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML
Pfizer
Phase 3 Completed
NCT03390296 2023-09-05
OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03416179 2023-04-21
BRIGHT AML1019
Pfizer
Phase 3 Completed
NCT01841333 2022-01-25
PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant
University of Colorado, Denver
Phase 2 Completed
NCT01842646 2021-06-14
Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT01546038 2020-03-03
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Pfizer
Phase 2 Completed